ArticlePediatric blood & cancer2010
Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children.
Article in Pediatric blood & cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.The Cochrane database of systematic reviews · 2014Pooled it
- Treatment of Kaposi sarcoma in children with HIV-1 infection.The Cochrane database of systematic reviews · 2014Pooled it
- Review
- Pediatric HIV+ Kaposi sarcoma exhibits clinical, virological, and molecular features different from the adult disease.JCI insight · 2023Article
- Divergent clinical presentations and outcomes among children and adolescents with Kaposi sarcoma in Malawi and Tanzania.HIV medicine · 2023Article
- Endemic Kaposi's Sarcoma.Cancers · 2023Review
- Health Service delivery and training at Makerere University College of Health Sciences: The role of the academic health centers' network.African health sciences · 2022Article
- Long-term outcomes for children and adolescents with Kaposi sarcoma.HIV medicine · 2022Article
- Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi's Sarcoma Patients.Cancers · 2020Article
- Navigating the heterogeneous landscape of pediatric Kaposi sarcoma.Cancer metastasis reviews · 2019Review
- HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.American journal of clinical dermatology · 2019Review
- KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions.International journal of cancer · 2019Observational
- Cancer prevention and control: Kaposi's sarcoma.Ecancermedicalscience · 2019Article
- Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi.Journal of global oncology · 2018Article
- Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives.Pediatric health, medicine and therapeutics · 2018Review
- Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease.Infectious agents and cancer · 2018Article
- Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Article
- High seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV) among HIV-1-infected children and adolescents in a non-endemic population.Medical microbiology and immunology · 2016Article
- Mapping the Epidemiology of Kaposi Sarcoma and Non-Hodgkin Lymphoma Among Children in Sub-Saharan Africa: A Review.Pediatric blood & cancer · 2016Review
- Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants.The Journal of infectious diseases · 2016Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundKaposi sarcoma (KS) is one of the most common pediatric cancers in sub-Saharan Africa. Few data are available about the clinical presentation or response to treatment of children with epidemic (HIV-associated) KS.
methodsMedical records of all children with KS and HIV infection referred to the Uganda Cancer Institute in Kampala, Uganda from October 2004 to June 2007 were reviewed. Charts were abstracted for age, sex, location of KS lesions at presentation, biopsy results, CD4 T-cell count and percentage, and KS treatment and outcome.
resultsSeventy-three children with epidemic KS were identified, 37 males and 36 females. The median age was 10.1 years (range 2-18). KS presented with lymph node (LN) involvement in 60% of cases. The median absolute and percentage CD4 T-cells at presentation were 210 cells/microl and 7.4%, respectively. Those children with lymphadenopathic KS were younger (mean difference 3.7 years; P = 0.01) and had higher CD4 T-cell counts (mean difference 242 cells/microl; P = 0.03) than those without LN involvement. Of 32 patients for whom outcome data were available, a complete response to chemotherapy and/or antiretroviral therapy was documented in 20 (62.5%) patients.
conclusionsIn comparison to cutaneous involvement, LN involvement of epidemic KS occurs at younger ages and at higher CD4 levels. This clinical presentation may reflect recent infection with human herpesvirus 8 followed by a rapid progression to malignancy. Favorable response to treatment was observed in the majority of cases, but prospective studies are needed to determine optimal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.